Europe
A study conducted by 23andMe and published in Nature Genetics identified a genetic risk factor tied to the loss of smell from COVID-19.
UCB has announced that it is acquiring Zogenix as part of plans to expand its reach into commercializing and developing treatments for rare diseases.
On 25 January, Lonza Bioscience Informatics and NNIT will host a free 60-minute webinar to discuss the key requirements of next generation Manufacturing Execution Systems (MES) and how small- and medium-sized companies can overcome critical implementation challenges for accelerated pharma digitalization.
Based on the success of a joint immuno-oncology antibody collaboration program targeting CD96, GlaxoSmithKline and 23andMe have extended their 2018 collaboration for an additional year.
The company will continue to analyze data regarding the secondary endpoints.
Evotec entered into a drug discovery collaboration for metabolic diseases with Eli Lilly, focusing on kidney disease and diabetes.
Studies are ongoing in Israel on whether a fourth dose of an mRNA vaccine offers additional protection. Although the data is still early, it suggests that it might not.
The Danish pharma giant is partnering with EraCal Therapeutics, to develop new obesity-related drug targets.
GlaxoSmithKline has declined all three of Unilever PLC’s offers to acquire its Consumer Healthcare business, saying that the proposal undervalued the division’s present and further worth.
Relief said that NRx’s claims that their partnership has been canceled were untrue and that it believes their collaboration involving aviptadil remains active and in full force.
PRESS RELEASES